PI: Armin Zebisch
Focus: Myeloid leukemias are devastating hematologic cancers with a dismal prognosis in affected patients. Our research group aims to delineate the molecular basis of myeloid leukemia development and use this knowledge to design novel treatment approaches. We are especially interested in the role of RAS-oncogenes, which are an essential component of many intracellular signal transduction cascades. They are potent drivers of leukemia development and are frequently mutated in human myeloid leukemia patients.
Network: Our international research group is located at the Division of Pharmacology, the Center for Medical Research (ZMF), and the Division of Hematology. This setting enables direct interaction with both basic and clinical scientists. Moreover, the team actively collaborates with renowned national and international experts. Our research covers the whole spectrum of preclinical leukemia research, including studies in genetically engineered leukemia mouse models and leukemic cell lines, where we perform cutting-edge techniques, such as CRISPR/Cas9 genome editing. Finally, our research also provides a strong translational aspect, as we extend our work to primary human leukemia patient specimens.